Norway – Medical equipments, pharmaceuticals and personal care products – 77454 Voluntary ex ante transparency notice
A structured breakdown of scope, eligibility requirements, submission steps, and key conditions — extracted directly from the official notice.
Sign in to unlock Bid Fit & AI Opportunity Intelligence
TenderZenith calculates a personalized qualification score against your company profile and extracts structured intelligence from tender documents with your 7-Day Pro Trial (No Credit Card Required).
Contract Description
77454 RA KRE – Cell processing equipment (Sepax C-Pro) with consumables and service – notice of intention to award a contract without prior publication of a call for competition Oslo University Hospital (OUS) intends to award a contract to Cytiva Europe GmbH, Norwegian Branch (filial Norge), for the purchase of one cell processing instrument (Sepax C-Pro) as a back-up for the existing validated instrument at the Section for Cell Therapy, Radiumhospitalet. The contract also includes a framework agreement for proprietary consumables (single-use kits) and service. The estimated total value is NOK 8.0 million excl. VAT over 10 years, and covers the instrument, consumables and service. Justification for the choice of procedure The contract is awarded without prior publication of a call for competition pursuant to Section 13-4, letter b, no. 2 of the Norwegian Public Procurement Regulations (anskaffelsesforskriften). The full justification is set out in the attached document “Justification for the award of a contract without prior publication of a call for competition”, dated 11 November 2026. Any objections must be submitted in writing to the contact person via Mercell within 10 days after publication of the notice.